| Literature DB >> 28144987 |
F Balducci1, S Canal1,2, B Contiero2, M Bernardini1,2.
Abstract
BACKGROUND: Ascending/descending myelomalacia (ADMM) is a severe complication of thoracolumbar intervertebral disk herniation (TL-IVDH) in dogs. HYPOTHESIS/Entities:
Keywords: Canine; Contusive injury; Deep pain perception; Spinal cord injury
Mesh:
Year: 2017 PMID: 28144987 PMCID: PMC5354033 DOI: 10.1111/jvim.14656
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Distribution of TL‐IVDH sites in all dogs with neurological signs graded 3, 4, and 5 and in dogs with ADMM
| Intervertebral Disk Site | Total Number of IVDH | No. (%) of ADMM Cases |
|---|---|---|
| T9‐T10 | 2 | 0 (0) |
| T10‐T11 | 9 | 0 (0) |
| T11‐T12 | 52 | 2 (3.85) |
| T12‐T13 | 94 | 3 (3.19) |
| T13‐L1 | 78 | 3 (3.85) |
| L1‐L2 | 58 | 1 (1.72) |
| L2‐L3 | 52 | 0 (0) |
| L3‐L4 | 27 | 0 (0) |
| L4‐L5 | 23 | 0 (0) |
| L5‐L6 | 5 | 4 (80) |
Number of dogs with and without ADMM, with neurological signs graded 3, 4, and 5, with intramedullary T2W hyperintensity and median T2 length ratio
| Neurological Grade | N° (%) of Dogs with Intramedullary T2W Hyperintensity | Median T2 Length Ratio | ||
|---|---|---|---|---|
| Dogs without ADMM | Dogs with ADMM |
| ||
| Grade 3 | 45 (26%) | 2.16 | — | — |
| Grade 4 | 56 (37.8%) | 3.14 | 4.67 | .166 |
| Grade 5 | 50 (90.9%) | 3.57 | 7.45 | <.001 |
— = Not applicable. Values of P < .05 were considered significant and based on Mann‐Whitney U‐test.
Results of univariate analysis to identify factors unconditionally associated with development of ADMM in 376 dogs after spinal decompression surgery for thoracolumbar IVDH
| Factor | No. (%) with ADMM | No. (%) without ADMM | OR | 95% CI |
|
|---|---|---|---|---|---|
| Breed | |||||
| Chondrodystrophic | 9 (69.2%) | 217 (59.8%) | 1.41 | 0.17–11.48 | .746 |
| Mixed | 3 (23.1%) | 112 (30.8%) | 0.91 | 0.09–9.06 | .938 |
| Nonchondrodystrophic | 1 (7.7%) | 34 (9.4%) | Referent | — | — |
| Age | |||||
| ≤5.8 year | 11(84.6%) | 189 (52.1%) | 5.06 | 1.11–23.17 | .021 |
| >5.8 year | 2 (15.4%) | 174 (47.9) | Referent | — | — |
| Sex | |||||
| Female | 8 (61.5%) | 158 (43.5%) | 2.07 | 0.66–6.46 | .198 |
| Male | 5 (38.5%) | 205 (56.5%) | Referent | — | — |
| Body weight | |||||
| ≤20.5 kg | 12 (92.3%) | 282 (77.7%) | 2.21 | 0.28–17.38 | .438 |
| >20.5 kg | 1 (7.7%) | 52 (22.3%) | Referent | — | — |
| Neurological grade | |||||
| Grade 5 | 8 (61.5%) | 47 (12.9%) | 10.75 | 3.37–34.26 | <.001 |
| Grade 3 and 4 | 5 (38.5%) | 316 (87.1%) | Referent | — | — |
| Site of IVDH | |||||
| L5‐L6 | 4 (30.8%) | 1 (0.3%) | 171.55 | 17.39–1692.14 | <.001 |
| Other | 9 (69.2%) | 386 (99.7%) | Referent | — | — |
| Duration of clinical signs to become nonambulatory | |||||
| ≤24 hours | 10 (76.9%) | 176 (48.5%) | 3.54 | 0.96–13.08 | .043 |
| >24 hours | 3 (23.1%) | 187 (51.5%) | Referent | — | — |
| Delay between loss of ability to walk and the neurological evaluation | |||||
| ≤24 h | 11 (84.6%) | 255 (70.2%) | 2.33 | 0.51‐10.69 | .263 |
| >24 h | 2 (15.4%) | 108 (29.8%) | Referent | — | — |
| Intramedullary T2W Hyperintensity | |||||
| Presence | 11 (84.6%) | 140 (38.6%) | 8.76 | 1.91–40.11 | <.001 |
| Absence | 2 (15.4%) | 223 (61.4%) | Referent | — | — |
| T2 length ratio | |||||
| >4.57 | 9 (81.8%) | 29 (20.7%) | 17.22 | 3.52–84.10 | <.001 |
| ≤4.57 | 2 (18.2%) | 111 (79.3%) | Referent | — | — |
— = Not applicable. Values of P < .05 were considered significant.
For percentage calculations, the denominator is the total number of dogs with ADMM (13) or without ADMM (363) for breed, age, sex, body weight, neurological grade, duration of clinical signs, delay, and intramedullary T2W hyperintensity.
For percentage calculations, the denominator is the total number of intervertebral disk sites affected in dogs with (13) or without ADMM (387) for site of IVDH.
For percentage calculations, the denominator is the number of dog with intramedullary T2W hyperintensity with (11) and without (140) ADMM for T2 length ratio.
Results of multivariate logistic regression to identify factors significantly associated with ADMM
| Factor | OR (95% CI) |
|
|---|---|---|
| Age ≤5.8 year (vs >5.8 year) | 3.71 (0.71–19.48) | .121 |
| Neurological grading 5 (vs 3 and 4) | 3.97 (0.98–16.09) | .053 |
| Duration of clinical signs≤24 hours (vs >24 hours) | 3.75 (0.89–15.88) | .072 |
| T2 length ratio >4.57 (vs ≤4.57) | 15.15 (2.90–79.13) | <.001 |
Values of P < .05 were considered significant.